Contact
Please use this form to send email to PR contact of this press release:
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
TO:
Please use this form to send email to PR contact of this press release:
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
TO: